BIOMARKER CEREBLON FOR DIAGNOSING HEPATOCELLULAR CARCINOMA, AND NOVEL MONOCLONAL ANTIBODY SPECIFIC THERETO

• Main Authors: HWANG, Sin, LEE, Kyung Jin
• Format: Patent
• Language: English; French; Korean
• Published: 01.10.2020
• Subjects: CHEMISTRY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; TESTING

The present invention relates to a use of Cereblon (CRBN) as a biomarker for diagnosing hepatocellular carcinoma, and a novel monoclonal antibody specific to Cereblon. More specifically, the present invention relates to a composition for diagnosing hepatocellular carcinoma or predicting a prognosis by using CRBN as a biomarker for diagnosing hepatocellular carcinoma, a kit, a method for providing information for diagnosing hepatocellular carcinoma or predicting a prognosis, two novel monoclonal antibodies that specifically bind to CRBN, and a hybridoma cell producing same. The difference in expression level of CRBN protein allows patients with hepatocellular carcinoma to be diagnosed early and indicates better predictive capabilities than the presence or absence of microvascular invasion, which was an important factor in predicting a prognosis of hepatocellular carcinoma in prior art, and thus can be expected to be used as a diagnostic marker to diagnose hepatocellular carcinoma and to evaluate a prognosis after hepatic resection. La présente invention concerne l'utilisation de céréblon (CRBN) en tant que biomarqueur pour le diagnostic d'un carcinome hépatocellulaire, et un nouvel anticorps monoclonal spécifique au céréblon. Plus particulièrement, la présente invention concerne une composition permettant de diagnostiquer un carcinome hépatocellulaire ou de prédire un pronostic à l'aide de CRBN en tant que biomarqueur pour diagnostiquer un carcinome hépatocellulaire, un kit, un procédé permettant de fournir des informations de diagnostic d'un carcinome hépatocellulaire ou de prédire un pronostic, deux nouveaux anticorps monoclonaux qui se lient de manière spécifique au CRBN, et une cellule d'hybridome produisant celui-ci. La différence du niveau d'expression de la protéine CRBN permet de diagnostiquer de manière précoce des patients atteints d'un carcinome hépatocellulaire et d'indiquer de meilleures capacités prédictives que la présence ou l'absence d'invasion microvasculaire, qui était un facteur important dans la prédiction d'un pronostic du carcinome hépatocellulaire dans l'état de la technique, et peut donc être utile en tant que marqueur de diagnostic pour diagnostiquer un carcinome hépatocellulaire et pour évaluer un pronostic après résection hépatique. 본 발명은 간세포암 진단용 바이오마커로서의 세레브론의 용도 및 세레브론 (Cereblon, CRBN)에 특이적인 신규한 단일클론항체에 관한 것으로, 보다 상세하게는 CRBN을 간세포암 진단용 바이오마커로 하여, 간세포암를 진단하거나 또는 예후를 예측하기 위한 조성물, 키트, 간세포암의 진단 또는 예후 예측을 위한 정보제공방법, CRBN에 특이적으로 결합하는 2종의 신규한 단일클론항체 및 이를 생산하는 하이브리도마 세포에 관한 것이다. CRBN 단백질의 발현량 차이는 간세포암 환자의 조기 진단뿐만 아니라, 종래 간세포암 예후 예측에 중요한 인자인 미세혈관 침윤 여부보다 더욱 뛰어난 예측력을 나타내어 간세포암 진단 및 간 절제 수술 후 예후를 평가하기 위한 진단 마커로서 활용될 수 있을 것으로 기대된다.